AU2019304014B2 - A xinafoate salt of a jak inhibiting compound - Google Patents

A xinafoate salt of a jak inhibiting compound Download PDF

Info

Publication number
AU2019304014B2
AU2019304014B2 AU2019304014A AU2019304014A AU2019304014B2 AU 2019304014 B2 AU2019304014 B2 AU 2019304014B2 AU 2019304014 A AU2019304014 A AU 2019304014A AU 2019304014 A AU2019304014 A AU 2019304014A AU 2019304014 B2 AU2019304014 B2 AU 2019304014B2
Authority
AU
Australia
Prior art keywords
fluoro
formula
xinafoate salt
methylpiperazin
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019304014A
Other languages
English (en)
Other versions
AU2019304014A1 (en
Inventor
Carl-Johan Aurell
James Mccabe
Anna Matilda Angelica Pettersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2019304014A1 publication Critical patent/AU2019304014A1/en
Application granted granted Critical
Publication of AU2019304014B2 publication Critical patent/AU2019304014B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019304014A 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound Active AU2019304014B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862699955P 2018-07-18 2018-07-18
US62/699,955 2018-07-18
US201962866013P 2019-06-25 2019-06-25
US62/866,013 2019-06-25
PCT/EP2019/069252 WO2020016302A1 (en) 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound

Publications (2)

Publication Number Publication Date
AU2019304014A1 AU2019304014A1 (en) 2021-03-04
AU2019304014B2 true AU2019304014B2 (en) 2022-08-18

Family

ID=67396927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019304014A Active AU2019304014B2 (en) 2018-07-18 2019-07-17 A xinafoate salt of a jak inhibiting compound

Country Status (14)

Country Link
US (1) US11149029B2 (https=)
EP (1) EP3823964A1 (https=)
JP (2) JP7422732B2 (https=)
KR (1) KR102849420B1 (https=)
CN (2) CN118580223A (https=)
AU (1) AU2019304014B2 (https=)
BR (1) BR112021000467A2 (https=)
CA (1) CA3105585A1 (https=)
IL (1) IL280025B2 (https=)
MA (1) MA53162A (https=)
MX (1) MX2021000611A (https=)
MY (1) MY209356A (https=)
SG (1) SG11202100240RA (https=)
WO (1) WO2020016302A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
GB202316063D0 (en) 2023-10-20 2023-12-06 Astrazeneca Ab Dosing regime
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134213A1 (en) * 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031011A2 (en) 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
MX2013003019A (es) * 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
AU2014342338B2 (en) * 2013-11-01 2016-12-01 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
PL3189045T3 (pl) 2014-08-11 2022-04-04 Sun Pharmaceutical Industries Limited Nowe sole nilotynibu i jego polimorfy
BR112018005833B1 (pt) * 2015-09-25 2023-10-10 Dizal (Jiangsu) Pharmaceutical Co., Limited Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134213A1 (en) * 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors

Also Published As

Publication number Publication date
IL280025B1 (en) 2024-10-01
KR102849420B1 (ko) 2025-08-25
WO2020016302A1 (en) 2020-01-23
BR112021000467A2 (pt) 2021-04-06
WO2020016302A8 (en) 2020-11-12
JP2024001109A (ja) 2024-01-09
MA53162A (fr) 2021-05-26
CN112424187B (zh) 2024-06-21
IL280025A (en) 2021-03-01
AU2019304014A1 (en) 2021-03-04
SG11202100240RA (en) 2021-02-25
MY209356A (en) 2025-07-03
MX2021000611A (es) 2021-04-13
EP3823964A1 (en) 2021-05-26
CN112424187A (zh) 2021-02-26
US11149029B2 (en) 2021-10-19
KR20210033474A (ko) 2021-03-26
CA3105585A1 (en) 2020-01-23
CN118580223A (zh) 2024-09-03
IL280025B2 (en) 2025-02-01
US20200062737A1 (en) 2020-02-27
JP7422732B2 (ja) 2024-01-26
JP7644190B2 (ja) 2025-03-11
JP2021530526A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
JP7644190B2 (ja) Ｊａｋ阻害化合物のキシナホ酸塩
TWI549953B (zh) ７－環戊基－２－（５－哌－１－基－吡啶－２－基胺基）－７ｈ－吡咯并［２，３－ｄ］嘧啶－６－羧酸二甲醯胺之鹽類及其製備方法
CN111875585B (zh) 一类激酶抑制剂
JP7797486B2 (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
CA3034010A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2009062059A2 (en) Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
JP2020504747A (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
TW201738232A (zh) 吲唑之合成
TWI851336B (zh) 腺苷受體拮抗劑化合物
TW202112768A (zh) 二取代吡唑化合物
EP4393917A1 (en) Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP3426640A1 (en) Prmt5 inhibitors
WO2018170199A1 (en) Forms and compositions of a mk2 inhibitor
CN113302196A (zh) Egfr抑制剂及其组合物和应用
CN113372351A (zh) 一类jak激酶抑制剂及其制备和应用
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用
US20250059199A1 (en) Solid forms of a tyk2 inhibitor, method of preparation, and use thereof
EA044028B1 (ru) Ксинафоатная соль соединения, ингибирующего jak
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
CN103339124A (zh) 二(芳氨基)芳基化合物的制备方法及其合成中间体
CN121605107A (zh) 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法
CN121449616A (zh) 靶向降解细胞周期依赖性激酶的化合物及其制备方法、药物组合物和用途
WO2025003769A2 (zh) 芳杂环并吡咯烷酮类衍生物及其用途
HK1185617A (en) Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
HK1185617B (en) Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)